IT Field of Competence Digital Health: Reference Story Biotronik

aq_block_3

Medical Technology that Saves Lives

BIOTRONIK is committed to helping people with heart and blood vessel diseases live healthy, fulfilling lives. This immense responsibility motivates thousands of its employees worldwide to develop new cardiovascular and endovascular medical technologies that physicians trust to save and improve patients’ lives. The company’s unique, safe and reliable products, including pacemakers, stents, implantable defibrillators and remote monitoring services, help patients in more than 100 countries.

Setting the Pace, Pioneering the Future with BIOTRONIK Home Monitoring

One of the core principles is innovating medical technology in the field of cardiology. Since the founder Max Schaldach developed the first German pacemaker in 1963, the company has paved the way for pioneering innovations. BIOTRONIK places utmost importance on research and development in order to continuously improve the diagnosis, treatment and prevention of cardiovascular and endovascular disease. At the Berlin headquarters alone, one out of every five employees works in Research and Development, ensuring that medical technology keeps pace with the interests and needs of future patients and physicians.

In 2000, BIOTRONIK was the first company to combine medical technology with telecommunication to enable the automatic, daily transfer of patients’ clinical and device data to their physician. BIOTRONIK Home Monitoring remains the most reliable, effective and convenient remote monitoring system on the market, with millions of patients, physicians and clinics worldwide relying on its quality.

BIOTRONIK Home Monitoring Also Reduces Mortality

The meta-analysis TRUECOIN[1] demonstrates again: BIOTRONIK Home Monitoring reduces mortality for of all types of ICD patients. This is associated with a 38 percent reduced risk of all-cause mortality after one year across all implantable cardioverter defibrillator (ICD) indications. TRUECOIN investigators observed these results in comparison with conventional in-office follow-up for ICD patients. Furthermore, they also found a 36 percent reduction in the combined risk of all-cause mortality or hospitalization for worsening heart failure.

First presented by Dr. Gerhard Hindricks, Leipzig Heart Center, Germany, at the European Society of Cardiology’s 2016 conference in Rome, the meta-study pooled 2,405 patients from three previous Home Monitoring trials: TRUST[2], ECOST[3] and IN-TIME[4]. The IN-TIME trial, published in The Lancet, showed a more than 50 percent risk reduction for all-cause mortality in heart failure patients specifically. Results of the new study show the extended mortality benefit of Home Monitoring to all ICD patients.

“The results suggest BIOTRONIK Home Monitoring is effective in helping to reduce mortality in patients with a wide variety of ICD indications and to slow the progression of heart failure,” commented Dr. Hindricks, TRUECOIN lead investigator. “We observed these benefits by analysing studies that only used Home Monitoring, rather than combining data from patients followed using systems that have differing operational features. Hence, analyzing individual remote monitoring systems may be preferred over global analyses.” Dr. Hindricks further highlighted that not all remote monitoring systems are the same. The automatic, daily transmission of a specific multi-parametric data set is unique to BIOTRONIK Home Monitoring.
This technology is the only remote monitoring system on the market that demonstrates a significant reduction of clinically relevant endpoints in randomized controlled trials. Additionally, proper management guidelines (standard operating procedures) must be in place in order to adequately respond to relevant patient alerts, such as for required changes to drug or device therapy. According to Dr. Hindricks, these factors appear to have a significant influence on patient well-being.

Website Biotronik

Photo: Biotronik SE & Co. KG




[1] Hindricks G et al., Daily remote monitoring of implantable cardioverter-defibrillators: Pooled individual patient data from IN-TIME, ECOST, and TRUST trials suggest a mechanism of clinical benefit, ESC Congress 2016, Rome.
[2] Varma N, et al. Eur Heart J. 2014, 35 (20).
[3] Guedon-Moreau L, et al. Europace. 2014, 16(8).
[4] Hindricks G, et al. The Lancet. 2014, 384 (9943).

More Reference Stories from the IT Field of Competence Digital Health

Newsenselab: M-Sense – an app brings relief for migraine and tension headache

40 percent of all Germans suffer from migraine and tension headache. Now help is at hand for the many patients in the shape of a mobile application. M-sense was recently released as the first migraine and tension headache app to be certified as a medical product. It was developed in Berlin. Read more ...